Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom GlobeNewswire - Wed Jul 22, 5:00AM CDT

STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 GlobeNewswire - Mon Jul 20, 5:00AM CDT

STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 GlobeNewswire - Thu Jul 16, 6:30AM CDT

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 GlobeNewswire - Thu Jul 9, 5:00AM CDT

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026 GlobeNewswire - Mon Jun 1, 7:15AM CDT

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing GlobeNewswire - Mon Jun 1, 5:00AM CDT

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing GlobeNewswire - Fri May 22, 3:30PM CDT

STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing GlobeNewswire - Thu Apr 30, 5:00AM CDT

STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 GlobeNewswire - Thu Apr 23, 5:00AM CDT

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing GlobeNewswire - Wed Apr 22, 4:00PM CDT

STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 12.98 (-1.59%)

Barchart Exclusives

Tesla Missed by 38% But Elon Musk Is Not Worried. Here’s What TSLA Investors Should Make of That. Barchart - Sun Jul 26, 4:38PM CDT
Tesla posted mixed Q2 results, but CEO Elon Musk assured investors of incredible returns following heavy capex. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.